Although conventional intervention to microglia can mitigate
neuroinflammation
in the short term, immune disorders by peripheral inflammatory cells
can infiltrate continuously, resulting in an overactivated immune
microenvironment of Parkinson’s disease (PD). Here, we design
engineered extracellular vesicle-based nanoformulations (EVNs) to
address multiple factors for the management of PD. Specifically, EVN
is developed by coating CCR2-enriched mesenchymal stem cell-derived
extracellular vesicles (MSCCCR2 EVs) onto a dihydrotanshinone
I-loaded nanocarrier (MSeN-DT). The MSCCCR2 EVs (the shell
of EVN) can actively show homing to specific chemokines CCL2 in the
substantia nigra, which enables them to block the infiltration of
peripheral inflammatory cells. Interestingly, MSeN-DT (the core of
EVN) can promote the Nrf2–GPX4 pathway for the suppression
of the source of inflammation by inhibiting ferroptosis in microglia.
In the PD model mice, a satisfactory therapeutic effect is achieved,
with inhibition of peripheral inflammatory cell infiltration, precise
regulation of inflammatory microglia in the substantia nigra, as well
as promotion of behavioral improvement and repairing damaged neurons.
In this way, the combinatorial code of alleviation of inflammation
and modulation of immune homeostasis can reshape the immune microenvironment
in PD, which bridges internal anti-inflammatory and external immunity.
This finding reveals a comprehensive therapeutic paradigm for PD that
breaks the vicious cycle of immune overactivation.